Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals



Date: 7th February, 2024 To, The Manager, Bombay Stock Exchange Limited, Department of Corporate Services P.J Towers, Dalal Street, Mumbai 400001

Scrip Code: 540359

<u>Sub: Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

Dear Sirs,

With reference to the captioned subject, we would like to inform you that the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Wednesday, 14th February, 2024 at 04.30 PM inter alia to consider, approve the Unaudited Financial Results of the quarter and Nine months ended on 31st December, 2023 and to discuss any other matter with the permission of Board.

Under our letter dated 30th December, 2023, we had communicated closure of trading window in respect of the Company with immediate effect till 48 hours after public announcement of the Audited Financial Results for the quarter and Nine months ended on 31st December, 2023. Consequently, the Trading Window will remain closed till 16th February, 2024.

You are requested to kindly take the above information on your record.

Thanking you,

Yours faithfully,

For Parmax Pharma Limited

Umang Gosalia Managing Director